FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123858165> ?p ?o ?g. }

• W2123858165 endingPage "692" @default.
• W2123858165 startingPage "684" @default.
• W2123858165 abstract "Because PGE1 previously has been reported to increase survival of patients with ARDS, we evaluated physiologic effects and side effects of PGE1 in a prospective open-label study of patients with ARDS. Seventeen patients with ARDS who did not have significant renal or hepatic dysfunction received PGE1 by continuous central venous infusion (30 ng/kg/min). Seventeen control patients with ARDS without renal or hepatic dysfunction who had similar APACHE II and ARDS scores and causes of ARDS did not receive PGE1. Prostaglandin E1 significantly decreased the SVRI and oxygen extraction ratio. Concentrations of total and polymorphonuclear leukocytes, but not platelets, increased significantly during PGE1 infusion, but did not change in control patients. There was no change in the DO2I and V ˙ O2I during the course of the PGE1 infusion. There were no differences in DO2I and V ˙ O2I during PGE1 infusion between survivors and nonsurvivors. Prostaglandin E1 was infused for a mean of 5.9 ± 1.8 days (± SD) and was discontinued on ten occasions in seven patients because of supraventricular dysrhythmias (n = 4), hypotension (n = 3), thrombocytopenia (n = 3), and cardiac arrest (n = 2). ***Nonsurvivors had PGE1 discontinued prematurely more frequently than survivors (56 percent [5/9] vs 25 percent [2/8], respectively). The prevalence of multiple-system organ failure and the in-hospital mortality of both PGE1-treated and control patients were not different. Although PGE1 causes significant systemic vasodilation and possibly decreased intrapulmonary polymorphonuclear leukocyte sequestration, PGE1 does not influence multiple-system organ failure or mortality of patients with ARDS without renal or hepatic dysfunction. Because PGE1 previously has been reported to increase survival of patients with ARDS, we evaluated physiologic effects and side effects of PGE1 in a prospective open-label study of patients with ARDS. Seventeen patients with ARDS who did not have significant renal or hepatic dysfunction received PGE1 by continuous central venous infusion (30 ng/kg/min). Seventeen control patients with ARDS without renal or hepatic dysfunction who had similar APACHE II and ARDS scores and causes of ARDS did not receive PGE1. Prostaglandin E1 significantly decreased the SVRI and oxygen extraction ratio. Concentrations of total and polymorphonuclear leukocytes, but not platelets, increased significantly during PGE1 infusion, but did not change in control patients. There was no change in the DO2I and V ˙ O2I during the course of the PGE1 infusion. There were no differences in DO2I and V ˙ O2I during PGE1 infusion between survivors and nonsurvivors. Prostaglandin E1 was infused for a mean of 5.9 ± 1.8 days (± SD) and was discontinued on ten occasions in seven patients because of supraventricular dysrhythmias (n = 4), hypotension (n = 3), thrombocytopenia (n = 3), and cardiac arrest (n = 2). ***Nonsurvivors had PGE1 discontinued prematurely more frequently than survivors (56 percent [5/9] vs 25 percent [2/8], respectively). The prevalence of multiple-system organ failure and the in-hospital mortality of both PGE1-treated and control patients were not different. Although PGE1 causes significant systemic vasodilation and possibly decreased intrapulmonary polymorphonuclear leukocyte sequestration, PGE1 does not influence multiple-system organ failure or mortality of patients with ARDS without renal or hepatic dysfunction." @default.
• W2123858165 created "2016-06-24" @default.
• W2123858165 creator A5018321818 @default.
• W2123858165 creator A5060270776 @default.
• W2123858165 creator A5090576091 @default.
• W2123858165 date "1990-03-01" @default.
• W2123858165 modified "2023-10-16" @default.
• W2123858165 title "Physiologic Effects and Side Effects of Prostaglandin E1 in the Adult Respiratory Distress Syndrome" @default.
• W2123858165 cites W1582972609 @default.
• W2123858165 cites W1970621150 @default.
• W2123858165 cites W1976714896 @default.
• W2123858165 cites W1983969834 @default.
• W2123858165 cites W1990986033 @default.
• W2123858165 cites W1991024307 @default.
• W2123858165 cites W1998433395 @default.
• W2123858165 cites W2002851538 @default.
• W2123858165 cites W2003673873 @default.
• W2123858165 cites W2005357317 @default.
• W2123858165 cites W2006474258 @default.
• W2123858165 cites W2018245631 @default.
• W2123858165 cites W2033783508 @default.
• W2123858165 cites W2041636767 @default.
• W2123858165 cites W2045172685 @default.
• W2123858165 cites W2056800858 @default.
• W2123858165 cites W2061934161 @default.
• W2123858165 cites W2070440319 @default.
• W2123858165 cites W2085042524 @default.
• W2123858165 cites W2130270365 @default.
• W2123858165 cites W2414677358 @default.
• W2123858165 cites W4293242440 @default.
• W2123858165 cites W4299783108 @default.
• W2123858165 doi "https://doi.org/10.1378/chest.97.3.684" @default.
• W2123858165 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2306970" @default.
• W2123858165 hasPublicationYear "1990" @default.
• W2123858165 type Work @default.
• W2123858165 sameAs 2123858165 @default.
• W2123858165 citedByCount "21" @default.
• W2123858165 countsByYear W21238581652012 @default.
• W2123858165 countsByYear W21238581652021 @default.
• W2123858165 crossrefType "journal-article" @default.
• W2123858165 hasAuthorship W2123858165A5018321818 @default.
• W2123858165 hasAuthorship W2123858165A5060270776 @default.
• W2123858165 hasAuthorship W2123858165A5090576091 @default.
• W2123858165 hasConcept C126322002 @default.
• W2123858165 hasConcept C141983124 @default.
• W2123858165 hasConcept C2776348555 @default.
• W2123858165 hasConcept C2777080012 @default.
• W2123858165 hasConcept C2777714996 @default.
• W2123858165 hasConcept C2778384902 @default.
• W2123858165 hasConcept C2778426790 @default.
• W2123858165 hasConcept C2779837120 @default.
• W2123858165 hasConcept C2780807750 @default.
• W2123858165 hasConcept C42219234 @default.
• W2123858165 hasConcept C71924100 @default.
• W2123858165 hasConcept C90924648 @default.
• W2123858165 hasConceptScore W2123858165C126322002 @default.
• W2123858165 hasConceptScore W2123858165C141983124 @default.
• W2123858165 hasConceptScore W2123858165C2776348555 @default.
• W2123858165 hasConceptScore W2123858165C2777080012 @default.
• W2123858165 hasConceptScore W2123858165C2777714996 @default.
• W2123858165 hasConceptScore W2123858165C2778384902 @default.
• W2123858165 hasConceptScore W2123858165C2778426790 @default.
• W2123858165 hasConceptScore W2123858165C2779837120 @default.
• W2123858165 hasConceptScore W2123858165C2780807750 @default.
• W2123858165 hasConceptScore W2123858165C42219234 @default.
• W2123858165 hasConceptScore W2123858165C71924100 @default.
• W2123858165 hasConceptScore W2123858165C90924648 @default.
• W2123858165 hasIssue "3" @default.
• W2123858165 hasLocation W21238581651 @default.
• W2123858165 hasLocation W21238581652 @default.
• W2123858165 hasOpenAccess W2123858165 @default.
• W2123858165 hasPrimaryLocation W21238581651 @default.
• W2123858165 hasRelatedWork W2003298541 @default.
• W2123858165 hasRelatedWork W2066356997 @default.
• W2123858165 hasRelatedWork W2076444960 @default.
• W2123858165 hasRelatedWork W2123858165 @default.
• W2123858165 hasRelatedWork W2154581887 @default.
• W2123858165 hasRelatedWork W2289222747 @default.
• W2123858165 hasRelatedWork W2315731226 @default.
• W2123858165 hasRelatedWork W2418962097 @default.
• W2123858165 hasRelatedWork W4248756531 @default.
• W2123858165 hasRelatedWork W4299783108 @default.
• W2123858165 hasVolume "97" @default.
• W2123858165 isParatext "false" @default.
• W2123858165 isRetracted "false" @default.
• W2123858165 magId "2123858165" @default.
• W2123858165 workType "article" @default.